1 |
0.9% sodium chloride |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
006 [4] 6 , 14, 51, 53 💬 |
2 |
0.9% sodium chloride (normal saline) |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
006 [1] 6 💬 |
3 |
0.9% sodium chloride injection |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
168 [1] 168 💬 |
4 |
0.9% w/v isotonic sodium chloride solution |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
050 [1] 50 💬 |
5 |
0.9% w/v sodium chloride solution |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
299 [1] 299 💬 |
6 |
Continuous infusion meropenem |
Meropenem |
[2] D02222 D02222, D08185 D08185 💬 |
- |
- |
299 [1] 299 💬 |
7 |
Dexmedetomidine |
Dexmedetomidine |
[2] D00514 D00514, D01205 D01205 💬 |
ADRA2A [3] ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
002 [12] 2 , 4 , 6 , 21, 34, 46, 70, 113, 212, 215, 226, 280 💬 |
8 |
Dexmedetomidine 1 |
Dexmedetomidine |
[2] D00514 D00514, D01205 D01205 💬 |
ADRA2A [3] ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
280 [1] 280 💬 |
9 |
Dexmedetomidine 2 |
Dexmedetomidine |
[2] D00514 D00514, D01205 D01205 💬 |
ADRA2A [3] ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
280 [1] 280 💬 |
10 |
Dexmedetomidine 3 |
Dexmedetomidine |
[2] D00514 D00514, D01205 D01205 💬 |
ADRA2A [3] ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
280 [1] 280 💬 |
11 |
Dexmedetomidine group |
Dexmedetomidine |
[2] D00514 D00514, D01205 D01205 💬 |
ADRA2A [3] ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
070 [1] 70 💬 |
12 |
Dexmedetomidine hydrochloride |
Dexmedetomidine |
[2] D00514 D00514, D01205 D01205 💬 |
ADRA2A [3] ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
070 [1] 70 💬 |
13 |
Dexmedetomidine hydrochloride infusion |
Dexmedetomidine |
[2] D00514 D00514, D01205 D01205 💬 |
ADRA2A [3] ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
006 [1] 6 💬 |
14 |
Dexmedetomidine with ropivacaine |
Dexmedetomidine |
[4] D00514 D00514, D01205 D01205, D04048 D04048, D08490 D08490 💬 |
ADRA2A [8] ADRA2A, ADRA2B, ADRA2C, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes [5] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Neuroactive ligand-receptor interaction, Taste transduction, cGMP-PKG signaling pathway |
070 [1] 70 💬 |
15 |
Fentanyl (low dose) + dexmedetomidine |
Dexmedetomidine |
[4] D00320 D00320, D00514 D00514, D01205 D01205, D01399 D01399 💬 |
ADRA2A [4] ADRA2A, ADRA2B, ADRA2C, OPRM1 💬 |
Estrogen signaling pathway [4] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
215 [1] 215 💬 |
16 |
Fluconazole |
Fluconazole |
[2] D00322 D00322, D01429 D01429 💬 |
- |
- |
096 [2] 96, 225 💬 |
17 |
Intermittent, short infusion meropenem |
Meropenem |
[2] D02222 D02222, D08185 D08185 💬 |
- |
- |
299 [1] 299 💬 |
18 |
Isotonic sodium chloride solution |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
034 [1] 34 💬 |
19 |
Iv meropenem |
Meropenem |
[2] D02222 D02222, D08185 D08185 💬 |
- |
- |
299 [1] 299 💬 |
20 |
Levetiracetam |
Levetiracetam |
[1] D00709 D00709 💬 |
SV2A [1] SV2A 💬 |
ECM-receptor interaction [1] ECM-receptor interaction |
002 [4] 2 , 4 , 6 , 13 💬 |
21 |
Meropenem |
Meropenem |
[2] D02222 D02222, D08185 D08185 💬 |
- |
- |
060 [2] 60, 299 💬 |
22 |
Meropenem fresenius kabi |
Meropenem |
[2] D02222 D02222, D08185 D08185 💬 |
- |
- |
299 [1] 299 💬 |
23 |
Meropenem fresenius kabi 1 g poeder voor oplossing voor injectie of infusie |
Meropenem |
[2] D02222 D02222, D08185 D08185 💬 |
- |
- |
299 [1] 299 💬 |
24 |
Meropenem infusion |
Meropenem |
[2] D02222 D02222, D08185 D08185 💬 |
- |
- |
299 [1] 299 💬 |
25 |
Meropenem trihydrate |
Meropenem |
[2] D02222 D02222, D08185 D08185 💬 |
- |
- |
299 [1] 299 💬 |
26 |
Other: 0.9% sodium chloride |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
065 [1] 65 💬 |
27 |
Other: 0.9ml sodium chloride |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
271 [1] 271 💬 |
28 |
Other: sodium chloride |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
051 [1] 51 💬 |
29 |
Physiological serum (sodium chloride) |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
193 [1] 193 💬 |
30 |
Procedure: 9% sodium chloride (nacl) iv |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
078 [1] 78 💬 |
31 |
Scopolamine, atropine, edaravone and dexmedetomidine |
Atropine |
[9] D00113 D00113, D00138 D00138, D00514 D00514, D01077 D01077, D01205 D01205, D01552 D01552, D02069 D02069, D03011 D03011, D03814 D03814 💬 |
ADRA2A [8] ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease [14] Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway |
002 [1] 2 💬 |
32 |
Sodium chloride |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
006 [20] 6 , 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 78, 96, 168, 193, 227, 228, 271, 288, 299 💬 |
33 |
Sodium chloride (7%) |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
299 [1] 299 💬 |
34 |
Sodium chloride 0,9% |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
299 [1] 299 💬 |
35 |
Sodium chloride 0.9% |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
014 [1] 14 💬 |
36 |
Sodium chloride 6% |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
299 [1] 299 💬 |
37 |
Sodium chloride 7% |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
299 [1] 299 💬 |
38 |
Sodium chloride ph. eur. |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
299 [1] 299 💬 |
39 |
Sodium chloride solution |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
011 [3] 11, 13, 228 💬 |
40 |
Sodium chloride solution 0.9% |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
060 [3] 60, 288, 299 💬 |
41 |
Sodium chloride solvent |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
228 [1] 228 💬 |
42 |
Sodium pyruvate in 0.9% sodium chloride solution |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
299 [1] 299 💬 |
43 |
Solucion de cloruro de sodio sodium chloride solution |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
228 [1] 228 💬 |
44 |
Solvente cloruro de sodio sodium chloride solvent |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
228 [1] 228 💬 |
45 |
Tranexamic acid |
Tranexamic acid |
[1] D01136 D01136 💬 |
PLG [1] PLG 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Influenza A, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection |
046 [5] 46, 70, 215, 227, 288 💬 |
46 |
Tranexamic acid 100 mg/ml |
Tranexamic acid |
[1] D01136 D01136 💬 |
PLG [1] PLG 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Influenza A, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection |
070 [1] 70 💬 |
47 |
Tranexamic acid injection [cyklokapron] |
Tranexamic acid |
[1] D01136 D01136 💬 |
PLG [1] PLG 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Influenza A, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection |
288 [1] 288 💬 |